alemtuzumab

Home
Ligands
alemtuzumab

GtoPdb Ligand ID: 6770

Synonyms: campath 1H | Campath® | campath-1H | Lemtrada®

alemtuzumab is an approved drug (FDA (2001), EMA (2013))

Comment: CAMPATH-1 (CD52) antigen inhibitor. Functionally, alemtuzumab causes depletion and then recovery of the immune system.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

View more information in the IUPHAR Pharmacology Education Project: alemtuzumab

References
1. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP. (1992) Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol, 87 (1): 105-10. [PMID:1339322]
2. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res, 22 (2): 185-91. [PMID:9593475]
3. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA et al.. (2016) Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 87 (19): 1985-1992. [PMID:27733571]
4. Shitara K, Niwa R, Natsume A. (2011) Recombinant antibody composition. Patent number: US7923538. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.
5. Shitara K, Niwa R, Natsume A. (2011) Recombinant antibody composition. Patent number: US7923538 B2. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.

References

1. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP. (1992)
Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.
Clin Exp Immunol, 87 (1): 105-10. [PMID:1339322]

2. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. (1998)
Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Leuk Res, 22 (2): 185-91. [PMID:9593475]

3. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA et al.. (2016)
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Neurology, 87 (19): 1985-1992. [PMID:27733571]

4. Shitara K, Niwa R, Natsume A. (2011)
Recombinant antibody composition.
Patent number: US7923538. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.

5. Shitara K, Niwa R, Natsume A. (2011)
Recombinant antibody composition.
Patent number: US7923538 B2. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.